Quality of Life and Health Economic Assessments of Age-Related Macular Degeneration

Survey of Ophthalmology

Volumn 52, Issue 1 SUPPL., 2007, Pages

  Covert, David ^a   Berdeaux, Gilles ^a   Mitchell, Jan ^b   Bradley, Clare ^b   Barnes, Rod ^a  

^a ALCON RESEARCH LTD   (United States)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

age related macular degeneration; cost of blindness and cost effectiveness; low vision; quality of life measures; visual function measures; visual impairment

Indexed keywords

ANECORTAVE; PEGAPTANIB; RANIBIZUMAB;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RETINA MACULA AGE RELATED DEGENERATION; SHORT FORM 36; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL DISORDER; VISUAL IMPAIRMENT;

BLINDNESS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HUMANS; MACULAR DEGENERATION; QUALITY OF LIFE; VISION, LOW;

EID: 33846251479     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2006.10.014     Document Type: Article

References (39)

1. Bonastre J., Le Pen C., Anderson P., et al. The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom. Eur J Health Econ 3 (2002) 94-102
2. Bradley C. The 12-Item Well-Being Questionnaire: origins, current stage of development, and availability. Diabetes Care 23 (2000) 875
3. Bradley C. The Well-being Questionnaire. In: Bradley C. (Ed). The Handbook of Psychology and Diabetes: A Guide to Psychological Measures in Diabetes Research and Practice (1994), Harwood Academic Press, Chur, Switzerland 89-109
4. Bradley C., Todd C., Gorton T., et al. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res 8 (1999) 79-91
5. Bressler N.M., Bressler S.B., Congdon N.G., et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 121 (2003) 1621-1624
6. Brezin A., Lafuma A., Fagnani F., et al. Prevalence and burden of self-reported blindness, low vision, and visual impairment in the French community: a nationwide survey. Arch Ophthalmol 123 (2005) 1117-1124
7. Brézin A.P., Lafuma A., Fagnani F., et al. Blindness, low vision, and other handicaps as risk factors attached to institutional residence. Br J Ophthalmol 88 (2004) 1330-1337
8. Brown G.C., Brown M.M., Sharma S., et al. Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. Ophthalmology 107 (2000) 1374-1380
9. Cassard S.D., Patrick D.L., Damiano A.M., et al. Reproducibility and responsiveness of the VF-14. An index of functional impairment in patients with cataracts. Arch Ophthalmol 113 (1995) 1508-1513
10. D'Amico D.J., Goldberg M.F., Hudson H., et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 110 (2003) 2372-2383 discussion 2384-5
11. Frick K.D., and Foster A. The magnitude and cost of global blindness: an increasing problem that can be alleviated. Am J Ophthalmol 135 (2003) 471-476
12. Klein R., Peto T., Bird A., et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol 137 (2004) 486-495
13. Mangione C.M., Berry S., Spritzer K., et al. Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Arch Ophthalmol 116 (1998) 227-233
14. Mangione C.M., Lee P.P., Gutierrez P.R., et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 119 (2001) 1050-1058
15. Mangione C.M., Lee P.P., Pitts J., et al. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol 116 (1998) 1496-1504
16. Mangione C.M., Phillips R.S., Seddon J.M., et al. Development of the 'Activities of Daily Vision Scale'. A measure of visual functional status. Med Care 30 (1992) 1111-1126
17. McGee H.M., O'Boyle C.A., Hickey A., et al. Assessing the quality of life of the individual: the SEIQoL with a healthy and a gastroenterology unit population. Psychol Med 21 (1991) 749-759
18. McMillan C.V., Bradley C., Gibney J., et al. Measuring psychological well-being in adult growth hormone deficency. Proc Br Psychol Soc 9 (2001) 71
19. Meads C., and Hyde C. What is the cost of blindness?. Br J Ophthalmol 87 (2003) 1201-1204
20. Mitchell J., and Bradley C. Design of an individualised measure of the impact of macular disease on quality of life (the MacDQoL). Qual Life Res 13 (2004) 1163-1175
21. Mitchell J., and Bradley C. Psychometric evaluation of the 12-item Well-being Questionnaire for use with people with macular disease. Qual Life Res 10 (2001) 465-473
22. Mitchell J., Bradley P., Anderson S.J., et al. Perceived quality of health care in macular disease: a survey of members of the Macular Disease Society. Br J Ophthalmol 86 (2002) 777-781
23. Mitchell J., Wolffsohn J.S., Woodcock A., et al. Psychometric evaluation of the MacDQoL individualised measure of the impact of macular degeneration on quality of life. Health Qual Life Outcomes 3 (2005) 25
24. National Institute for Clinical Excellence: Guidance on the use of photodynamic therapy for age-related macular degeneration. Technology Appraisal Guidance 68. September 2003. Reference N0305
25. Park W. Vision rehabilitation for age-related macular degeneration. Int Ophthalmol Clin 39 (1999) 143-162
26. Phillips K.A., Cockrum P.C., Kennedy R.H., et al. Worldwide blindness and prevention guidelines for front-line practitioners. Today's Therapeutic Trends 21 (2003) 71-83
27. Plowright R., Witthaus E., Bradley C., et al. Evaluating the 12-item Well-being Questionnaire for use in multinational trials. Qual Life Res 8 (1999) 650
28. Pouwer F., Snoek F.J., van der Ploeg H.M., et al. The well-being questionnaire: evidence for a three-factor structure with 12 items (W-BQ12). Psychol Med 30 (2000) 455-462
29. Pouwer F., van der Ploeg H.M., Adèr H.J., et al. The 12-item well-being questionnaire. An evaluation of its validity and reliability in Dutch people with diabetes. Diabetes Care 22 (1999) 2004-2010
30. Rabin R., and de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33 (2001) 337-343
31. Rubin G.S., Bandeen-Roche K., Huang G.H., et al. The association of multiple visual impairments with self-reported visual disability: SEE project. Invest Ophthalmol Vis Sci 42 (2001) 64-72
32. Rubin G.S., Roche K.B., Prasada-Rao P., et al. Visual impairment and disability in older adults. Optom Vis Sci 71 (1994) 750-760
33. Sharma S., Brown G.C., Brown M.M., et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 108 (2001) 2051-2059
34. Smith A.F., and Smith J.G. The economic burden of global blindness: a price too high. Br J Ophthalmol 80 (1996) 276-277
35. Speight J., Barendse S., and Bradley C. Impact of positively and negatively worded items on the factor structure of three psychological measures: W-BQ22, W-BQ12 & SF-36. Qual Life Res 8 (1999) 576
36. Taylor H.R., McCarty C.A., Nanjan M.B., et al. Vision impairment predicts five-year mortality. Trans Am Ophthalmol Soc 98 (2000) 91-96 discussion 96-9
37. Ware Jr. J.E., Snow K.K., Kosinski M., and Gandek B. SF-36 Health Survey: Manual and Interpretation Guide (1993), The Health Institute, New England Medical Center, Boston, MA
38. Williams R.A., Brody B.L., Thomas R.G., et al. The psychosocial impact of macular degeneration. Arch Ophthalmol 116 (1998) 514-520
39. Witthaus E., Stewart J., and Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabet Med 18 (2001) 619-625